Isabelle Tabah-Fisch, MD
Isabelle Tabah-Fisch, MD, a medical oncologist in Paris who contributed greatly to drug development, died August 28, 2020, at age 64. An announcement about Dr. Tabah-Fisch’s death was made by GamaMabs, where she served as Chief Medical Officer until her retirement in March 2020. Under her leadership, GamaMabs developed murlentamab (GM-102), a monoclonal antibody used to treat gynecologic and colorectal cancers.
Dr. Tabah-Fisch was born on November 30, 1955. She became a certified Doctor in Medicine in 1985 through the Paris Descartes University. She was board-certified in clinical hematology, bacteriology and virology, internal medicine, and clinical oncology.
Over the course of her career, Dr. Tabah-Fisch worked closely in drug development, performing research that contributed to the development of several novel anticancer therapies including oxaliplatin, docetaxel, caba-zi-taxel, ziv-aflibercept, and seribantumab. She held several important positions in industry, including Medical Director for Oncology/Hematology at Schering-Plough in France.
Dr. Tabah-Fisch served in several different positions for more than 20 years at Sanofi, including Vice President, Research and Development; Vice President, Corporate Medical Affairs; and Vice President, Head of Global Oncology Franchise. Later she worked at the biotechnology companies PDC*line Pharma, CarThera, and CleveXel Pharma. In 2016, Dr. Tabah-Fisch joined GamaMabs Pharma, where, under her leadership, the company developed murlentamab.
Dr. Tabah-Fisch was a member of the Women in Cancer Research group within the American Association for Cancer Research. She was also a member of ASCO and the European Society for Medical Oncology.
